InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,522.30
(
1.58%
)
US TECH 100
18,966.00
(
0.65%
)
Dow Jones
40,842.79
(
0.00%
)
Brent Oil
81.32
(
-0.24%
)
Bitcoin
64,628.77
(
0.05%
)
Post# of 652076
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

lukin4winners

Send PM Follow Ignore
Followers 797
Posts 118388
Boards Moderated 0
Alias Born 11/20/2004

lukin4winners

Re: Covid19freak post# 561206

Friday, 08/12/2022 7:23:34 AM

Friday, August 12, 2022 7:23:34 AM

Post# of 652076
EVANSTON, Ill., August 12, 2022--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results from a Phase 2b clinical study evaluating the effects of NYX-2925 in patients with fibromyalgia. NYX-2925 did not achieve statistically significant separation from placebo on the study’s primary endpoint, which assessed the change from baseline in average daily pain on the numeric rating scale (NRS) during week 12.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up